EVO Evotec SE

Nasdaq evotec.com


$ 4.06 $ 0.01 (0.25 %)    

Friday, 31-Oct-2025 15:59:46 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 4.07
$ 4.07
$ 4.00 x 100
$ 4.19 x 5
$ 4.03 - $ 4.09
$ 2.84 - $ 5.64
20,651
na
361.32M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continue...

 hc-wainwright--co-maintains-buy-on-evotec-lowers-price-target-to-7

HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $8 to...

 evotec-guides-2025-revenues-at-760m800m-adjusted-ebitda-at-30m50m-rd-spend-seen-at-40m50m

Guidance for full-year 2025Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m)R&D expenditures are expect...

 an-overview-of-evotecs-earnings
An Overview of Evotec's Earnings
08/12/2025 16:01:38

Core News & Articles

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUn...

 evotec-cuts-2025-revenue-forecast-to-760m800m-from-prior-840m-880m-amid-shifting-revenue-mix-and-weak-rd-market

Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480, NASDAQ:EVO) announce...

 evotecs-collaboration-sparks-hope-for-acute-kidney-injury-breakthroughs

Evotec shares rise after joining NURTuRE-AKI to advance kidney disease research through molecular data integration.

 evotec-joins-nurture-aki-to-unlock-precision-medicine-approaches-for-acute-kidney-injury-using-panomics-and-longitudinal-patient-data

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute ki...

 evotec-secures-25m-grant-to-generate-critical-data-supporting-new-tb-regimens

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuber...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION